"bharat-biotech"

Covaxin comprises a disabled form of SARS-CoV-2 that cannot replicate but still stimulates the immune system to make antibodies against the virus.

Dr Krishna Ella, CMD, Bharat Biotech, an alumnus of Anand Niketan College of Agriculture of Warora (Maharashtra), learnt in one of his regular call with the Anandwan management that the inmates were affected by the pandemic

It is reprehensible to invoke religious fears to spread falsehood against vaccines

Shortly afer the reports went viral after two major news channels began flashing the news, Bharat Biotech refuted these reports

"New born calf serum is used in the manufacturing of viral vaccines. It is used for the growth of cells, but neither used in growth of SARS CoV2 virus nor in the final formulation," the company said in a statement.

Compared to the first wave, the number of positive cases and their severity has increased among children this time.

Hyderabad firm stated that the data from efficacy and safety follow-up of Covaxin’s phase III trial is being analysed and compiled, and it will soon make the data from the final analysis public

With herd immunity and a significant percentage of the US population vaccinated, the pandemic is reducing, and keeping this in view, the USFDA communicated that no new emergency use authorization would be approved for new Covid-19 vaccines

The FDA recommended Ocugen to "pursue a Biologics Licence Application (BLA) submission instead of an EUA application" and "requested additional information and data".

These 44 crore doses of COVID-19 vaccines will be delivered by their makers between August and December 2021, the Union Health Ministry said.

Anvisa also approved a proposal to import Russia’s Sputnik V vaccine.

The Companies manufacturing COVID-19 vaccination in India have given only "Emergency Use Authorization for vaccinating people of 18 years age and above

US-based Ocugen will make an upfront payment and milestone payment upon first commercial sale in Canada to Bharat Biotech, in addition to sharing the profit from sales of Covaxin in Canada

For vaccines to result in actual vaccination of people, highly coordinated efforts are required from international supply chains, manufacturers, regulators and State and Central government agencies, says Bharat Biotech

Anvisa recently approved the Covaxin clinical trial in Brazil, which will study the application of two doses, with 28 days of interval, involving 4,500 volunteers

Anticipating the shortages, many States including Telangana had recently gone for global tenders

Regulatory approvals for Covaxin are in process in more than 60 countries including USA, Brazil and Hungary, says the Hyderabad company.

The daily vaccination rate has fallen to 1.3 million doses despite India not exporting the vaccines now

Hyderabad: Hyderabad-based Bharat Biotech said it will ramp up the manufacturing capacities for Covaxin, at Chiron Behring Vaccines, Ankleshwar Gujarat, a wholly owned subsidiary of Bharat Biotech. The company plans to produce 200 million (20 crore) doses of Covaxin per annum in the GMP facilities that are already operational for the production of vaccines based […]

Company plans to produce an additional 200 million doses of Covaxin per annum in the GMP facilities located at Ankleshwar, Gujarat, starting from the fourth quarter of 2021